MONTREAL, Nov. 23, 2017 /CNW/ - Today, at Innovative Medicines Canada's Annual General Meeting, Frédéric Fasano, Chief Executive Officer of Servier Canada Inc., was appointed Chair of the Board of Directors.
"I am honoured to serve as the next Chair of Innovative Medicines Canada and to drive forward its commitments to the Canadian life sciences ecosystem," said Frédéric Fasano. "I look forward to the opportunities and challenges ahead for the innovative pharmaceutical sector in Canada, and know that we can champion Canada as a great place to invest."
Mr. Fasano comes to his position with the Association at a time of great opportunity for the pharmaceutical industry. For the first time in many years, multiple initiatives are underway by governments to modernize the pharmaceutical policy and regulatory environment, processes in which the association is keen to participate and within which to bring innovative solutions forward.
Frédéric Fasano was appointed CEO of Servier Canada in 2011. Under his leadership, Servier opened its new Centre of Excellence for Clinical Research and a new regional office in Toronto. Together with two financial partners, Servier created ILKOS Therapeutics a biotechnology company located in Montreal.
"We are extremely pleased to welcome Frédéric Fasano as Chair of our Board of Directors at such an important time both for the country's innovative pharmaceutical industry and in the evolution of the Canadian healthcare system. We look forward to working with Mr. Fasano on key healthcare issues facing our industry, including access to new medicines and investing in Canada's life sciences ecosystem," said Pamela Fralick.
ABOUT INNOVATIVE MEDICINES CANADA
Innovative Medicines Canada is the national voice of Canada's innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members' commitment to being valued partners in the Canadian healthcare system.
SOURCE Innovative Medicines Canada
For further information: Sarah Dion-Marquis, Director, Media and Public Relations, Telephone: 613-769-6510, E-mail: [email protected]